Incidence of diabetes following ramipril or rosiglitazone withdrawal.

ABSTRACT:

Objective

To examine the impact of withdrawing rosiglitazone and ramipril medication on diabetes incidence after closeout of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

Research design and methods

The 3,366 DREAM subjects at trial end who had not developed diabetes while taking double-blind study medication were transferred to single-blind placebo for 2 to 3 months before undergoing an oral glucose tolerance test. Glycemic status was analyzed for the trial plus washout period and for the washout period alone.

Results

Following median (interquartile range) 71 (63-86) days drug withdrawal, overall glycemic status remained modestly improved in those allocated ramipril during the trial with an 11% increase in regression to n

SUBMITTER: DREAM Trial Investigators 

PROVIDER: S-EPMC3114353 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature